STOCK TITAN
  1. Home
  2. News
  3. ACLX

ARCELLX INC - ACLX STOCK NEWS

Welcome to our dedicated page for ARCELLX news (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on ARCELLX stock.

Arcellx Inc. (ACLX) is a clinical-stage biotechnology company pioneering controllable cell therapies for cancer and complex diseases. This page aggregates official press releases and verified news about ACLX's immunotherapy advancements, clinical trial progress, and regulatory developments.

Investors and researchers will find timely updates on key milestones including trial results, partnership announcements, and FDA communications. Our curated collection spans therapeutic innovations in multiple myeloma, acute myeloid leukemia, and emerging cell therapy platforms.

All content is sourced directly from company filings and reputable financial publications. Bookmark this page for centralized access to ACLX's latest scientific breakthroughs and strategic business decisions in the evolving cell therapy landscape.

News

Arcellx to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Arcellx, a biotechnology company focused on innovative immunotherapies for cancer, will participate in two upcoming investor conferences: BofA Securities Health Care Conference 2024 and TD Cowen 5th Annual Oncology Innovation Summit. The company aims to enhance its investor relations through these engagements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
conferences
-
News

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary
Arcellx, Inc. (ACLX) will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The company focuses on developing innovative immunotherapies for cancer and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences
-
News

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Rhea-AI Summary
Arcellx, Inc. (ACLX) to participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. The company focuses on developing innovative immunotherapies for cancer and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
conferences
News

Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary
Arcellx, Inc. (ACLX) will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference. The discussion will focus on the development of innovative immunotherapies for cancer and other diseases. A live webcast will be available on Arcellx's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
conferences
-
News

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights

Rhea-AI Summary
Arcellx, Inc. reported significant business and financial achievements for Q4 and full year 2023, including an expanded partnership with Kite Pharma, robust long-term responses from anito-cel Phase 1 trial, and ending the quarter with $729.2M cash. The company's continued progress in cell therapy development and strategic collaborations position it for future growth and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
earnings
-
News

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH

Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) announces promising clinical data from its Phase 1 expansion study of anitocabtagene autoleucel (anito-cel) for patients with relapsed or refractory multiple myeloma. The study shows deep and durable responses with a 100% overall response rate, 29 out of 38 patients achieved a complete response, and 35 out of 38 patients achieved a very good partial response or higher. The estimated median progression free survival for the study population was 28 months at the time of the data cut with 26.5 months of median follow-up. Anito-cel dosed at 115 million CAR+ T cells continues to be well-tolerated with manageable adverse events and no cases of grade 3 or greater CRS and only one case of grade 3 ICANS event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.87%
Tags
clinical trial
News

Kite and Arcellx Announce Expansion in Strategic Partnership

Rhea-AI Summary
Gilead (GILD) & Arcellx (ACLX) expand collaboration for CART-ddBCMA & ARC-SparX program ACLX-001. Kite exercises option to negotiate license for ARC-SparX program ACLX-001 in multiple myeloma. Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment. The collaboration aims to bring potentially best-in-class cell therapy to patients, expanding opportunities in lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
partnership
-
News

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), have expanded their collaboration, with Kite investing $200M at $61.68 per share and an $85 million upfront cash payment. Kite exercised its option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma and expanded the collaboration to include lymphomas. This investment is anticipated to extend Arcellx's cash runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
partnership
-
News

Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights

Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) reported positive results from its Phase 1 CART-ddBCMA trial with a median duration of response, progression free survival, and overall survival not reached in patients with a median follow-up of 22 months after infusion. The company will present new patient data from the trial during an oral presentation at the 65th ASH Annual Meeting in December, with a median follow-up of 26.5 months. The financial results for the third quarter ended September 30, 2023, show that Arcellx had cash, cash equivalents, and marketable securities of $482.7 million, and collaboration revenue was $15.0 million. Research and development expenses decreased to $43.8 million, and general and administrative expenses increased to $16.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.33%
Tags
earnings
News

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition

Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) will present new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma at the 65th American Society of Hematology (ASH) Annual Meeting. The data shows deep and durable responses in patients with poor prognostic factors, with an overall response rate of 100% and a complete response rate of 76%. The median duration of response, progression-free survival, and overall survival were not reached at the time of the data cut. The presentation will include new data with a median follow-up of 26.5 months. Arcellx will also host a live webcast event to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.55%
Tags
clinical trial
Stock ACLX logo
ARCELLX INC

Nasdaq:ACLX

ACLX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ACLX Stock Data

3.36B
50.28M
2.32%
107.57%
13.04%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
REDWOOD CITY